BC Platforms has closed a $15m Series C financing round, led by Iqvia and supported by Debiopharm and Tesi. The funds will be used to continue to expand BC Platform’s global footprint. At the same time BC Platforms and Iqvia announced a commercial partnership to launch new data-driven technologies integrating clinical and genomic data. These combined products are expected to drive transformational research and accelerate the use of precision medicine. BC Platforms is a Debiopharm Innovation Fund portfolio company.